Differential inhibition of PAF- and eotaxin-induced human eosinophil chemotaxis by wortmannin Source: Eur Respir J 2002; 20: Suppl. 38, 30s Year: 2002
Quantitative assessment of cysteinyl leukotrienes in human sputum during the allergen-induced asthmatic response and the effect of GSK2190915, a 5-lipoxygenase activating protein (FLAP) inhibitor Source: Annual Congress 2011 - Diagnosis and treatment of inflammatory respiratory diseases Year: 2011
Inhibition of eosinophil migration by montelukast, a cysteinyl leukotriene receptor antagonist, through down regulation of plasmin activity Source: Eur Respir J 2004; 24: Suppl. 48, 36s Year: 2004
Activation of second messenger pathways in alveolar macrophages by endotoxin Source: Eur Respir J 2002; 20: 210-222 Year: 2002
Interactive inhibitory effects of formoterol and montelukast on activated human neutrophils Source: Eur Respir J 2010; 36: 1417-1424 Year: 2010
GB001 potently inhibits PGD2 metabolite-induced DP2-mediated cell signaling and eosinophil activation Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms Year: 2020
Phosphoinositide 3-kinase δ inhibitor suppresses IL-17 expression in a murine model of asthma Source: Annual Congress 2009 - Animal models of airways inflammation Year: 2009
Phosphoinositide 3-kinase ? inhibitor suppresses interleukin-17 expression in a murine asthma model Source: Eur Respir J 2010; 36: 1448-1459 Year: 2010
Inhibition of basophil activation by adenosine and its agonists Source: Eur Respir J 2001; 18: Suppl. 33, 532s Year: 2001
Inhibition of P38 kinase does not reduce production of TNF-alpha from airway cells in COPD Source: Annual Congress 2007 - Epithelial networks in the airways Year: 2007
N-Acetylcysteine inhibits eotaxin and MCP-1 release in human airway smooth muscle cells in vitro through the inhibition of ROS production, resulting in a decrease of p38 MAP kinase activation Source: Eur Respir J 2002; 20: Suppl. 38, 170s Year: 2002
Group V phospholipase A2 (gVPLA2 ) -induced eosinophil synthesis of LTC4 is independent of mitogen-activated protein kinases (MAPK) activation Source: Eur Respir J 2001; 18: Suppl. 33, 408s Year: 2001
The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
Dual inhibition of thromboxane synthase and 5-lipoxygenase, potentially significant mechanism for the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
The inositol trisphosphate pathway mediates platelet-activating-factor-induced pulmonary oedema Source: Eur Respir J 2005; 25: 849-857 Year: 2005
COX-1 driven biosynthesis of PGD2 during activation of human mast cells prevents formation of other prostanoids Source: Virtual Congress 2020 – Novel molecular markers and targets for asthma phenotypes Year: 2020
Cilomilast, a second generation phosphodiestease 4 inhibitor, in combination with PGE2 attenuates fMLP, IL-8 and cigarette smoke-induced effects on the mechanical and functional properties of neutrophils Source: Eur Respir J 2001; 18: Suppl. 33, 161s Year: 2001
Phosphodiesterase 4 inhibition of β2-integrin adhesion caused by leukotriene B4 and TNF-α in human neutrophils Source: Eur Respir J 2006; 28: 920-928 Year: 2006
Transmission of muscarinic receptor mediated proliferative effects in human lung fibroblasts involves ERK-MAP kinase, but not PI-3 kinase and Rho-kinase pathway Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology Year: 2007
The pan janus kinase (JAK) inhibitor KN-002 suppresses inflammatory mediator release from severe asthma bronchial epithelial cells. Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021